Swiss firm Galderma has announced the launch of Sculptra, the first proven regenerative biostimulator with a unique poly-L-lactic acid (PLLA-SCA) formulation, in China. This follows Sculptra’s approval by China’s National Medical Products Administration for correcting mid-facial volume loss and/or contour deficiencies last year.
Sculptra – which works with the body’s natural processes to achieve healthier, radiant skin and a more youthful appearance – will now be available in China, where growth of aesthetics has outpaced the global market in the past decade. This launch is indicative of Galderma’s commitment to expanding its unparalleled aesthetics portfolio into new geographies, in order to meet the needs of even more patients and healthcare professionals.
China is a major market for Galderma, where sales have fueled the company’s strong performance across product categories. The aesthetics industry in China has also experienced remarkable growth in recent years, driven by increasing consumer demand for beauty and wellness treatments.
The market is expected to continue expanding at a rate of up to 15% in the coming years, and research has shown that many Chinese consumers prioritize the safety and outcomes of their aesthetic treatments. Sculptra is well placed to meet these expectations as its extensive safety profile and high satisfaction rate has been demonstrated in more than 10,000 patients in clinical studies over 25 years.
"Sculptra's introduction to the Chinese market marks a significant milestone in Galderma's growth journey. With over 25 years of proven clinical success, Sculptra’s launch not only underscores our commitment to providing premium, long-lasting, and natural-looking results, but also signifies Galderma's expansion into one of the world's most dynamic and rapidly growing aesthetics markets", said Baldo Scassellati Sforzolini, Global Head of Research & Development, Galderma.
